Corcept Therapeutics Incorporated (NASDAQ:CORT) is highlighted as one of the “Stocks That Could Mint Millionaires in 2026” by Insider Monkey. UBS analyst Ashwani Verma initiated coverage of CORT stock with a Neutral rating and $95 price target, citing valuation and the stock’s 64% year-to-date increase. The company reported Q3 earnings surpassing estimates but falling short of revenue expectations.

Corcept Therapeutics (NASDAQ:CORT) focuses on developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders in the U.S. Despite its potential, other AI stocks may offer higher returns with lower risks. For a promising undervalued AI stock benefiting from current trends, check out Insider Monkey’s report on the best short-term AI stock.

For more investment opportunities, Insider Monkey offers insights into 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for the Long Term. No disclosures related to Corcept Therapeutics Incorporated were provided.

Read more at Yahoo Finance: Analyst Says Shares Pricing in Growth, New Launch